The 9th JSH International Symposium 2018 in Kyoto

The 9th JSH International Symposium 2018 in Kyoto

Epigenetic Abnormalities and Therapies for Hematologic Malignancies エピジェネティクス異常による造血器腫瘍発症機構とその治療

Program

Epigenetic Abnormalities and Therapies for Hematologic Malignancies

Program (PDF)

Tentative Program

Friday, 27 July, 2018
8:50-9:00 Opening Remarks
9:00-10:00 Asian Session 1 : Hematological Leaders of Asia
Chair Dr. Hitoshi Kiyoi (Nagoya University Graduate School of Medicine)
Dr. Takahiro Maeda (Kyushu University Hospital)
Speaker Dr. Ai Kotani (Tokai University, School of Medicine)
Potent Microenvironment Changer: EBV Derived Exosome
Dr. Wen-Chien Chou (National Taiwan University Hospital, Chinese Taipei)
The Clinical and Biological Features of HOPX in de Novo Acute Myeloid Leukemia
Dr. Tao Cheng (Chinese Academy of Medical Sciences & Peking Union Medical College, China)
Incompetence of Normal Hematopoiesis in Leukemia and Its Mechanisms
Asian Session 2 : Hematological Leaders of Asia
Chair Dr. Issay Kitabayashi (National Cancer Center Research Institute)
Dr. Yoshinobu Kanda (Jichi Medical University)
Speaker Dr. Hao Jiang (People’s Hospital, Peking University, China)
Efficacy and Safety of Decitabine in Combination with G-CSF, Low-dose Cytarabine and Aclarubicin in MDS-EB and AML-MRC
Dr. Akihiko Yokoyama (National Cancer Center)
Transcriptional Mechanism that Drives MLL-Rearranged Leukemia
Dr. Yoo-Jin Kim (Seoul St.Mary’s Hospital, The Catholic University of Korea, Korea)
Hypomethylating Therapy in Stem Cell Transplantation for MDS
10:00-10:10 Break
10:10-11:50 Plenary Session 1 : Epigenetic Abnormalities of Hematological Malignancies; Basic Studies
Chair Dr. Takanori Teshima (Hokkaido University)
Dr. Hideo Harigae (Tohoku University Graduate School of Medicine)
Speaker Dr. Hiroaki Honda (Tokyo Women's Medical University)
Roles of Two Demethylases for Histone H3K27, JMJD3 and UTX, In Normal Hematopoiesis and Leukemogenesis
Dr. Daniel Starczynowski (Cincinnati Children's Hospital Medical Center : University of Cincinnati, USA)
Oncogenic Innate Immune Signaling in MDS and AML
Dr. Mineo Kurokawa (The University of Tokyo)
Modeling ASXL1 Mutation Revealed Impaired Hematopoiesis Caused by Derepression of p16Ink4a through Aberrant PRC1-mediated Histone Modification
Dr. Maria E. Figueroa (University of Miami Miller School of Medicine, USA)
Epigenetic Deregulation in Aging and MDS
11:50-12:05 Break
12:05-12:50 Luncheon Seminar 1 (Co-Sponsored by Chugai Pharmaceutical Co., Ltd.)
Chair Dr. Kenichi Ishizawa (Yamagata University)
Speaker Dr. Ari Melnick (Weill Cornell Medicine, USA)
Biology of Follicular Lymphoma
12:05-12:50 Luncheon Seminar 2 (Co-Sponsored by Celegine Corporation)
Chair Dr. Shinsuke Iida (Nagoya City University Graduate School of Medical Sciences)
Speaker Dr. Irene M. Ghobrial (Harvard Medical School : Steven and Michelle Kirsch Laboratory : Dana-Farber Cancer Institute, USA)
Multiple Myeloma: Disease Mechanism and Treatment Strategy
12:50-13:55 Poster Viewing
13:55-15:35 JSH-EHA Joint Session : Epigenetics of Myeloproliferative Neoplasm (MPN)
Chair Dr. Kinuko Mitani (Dokkyo Medical University School of Medicine)
Dr. Shinji Nakao (Kanazawa University)
Speaker Dr. Atsushi Iwama (Chiba University)
Deregulated Polycomb Functions in the Pathogenesis of Myeloproliferative Neoplasms
Dr. Kazuya Shimoda (University of Miyazaki)
The Role of Wild-Type and Mutant Calreticulin in Hematopoiesis
Dr. Radek C. Skoda (University Hospital Basel, Switzerland)
Molecular Pathogenesis of Myeloproliferative Neoplasms
Dr. Tony Green (University of Cambridge, UK)
Myeloproliferative Neoplasms-from Pathogenesis to Phenotypes and Personalized Predictions
15:35-15:55 Break
15:55-17:35 Plenary Session 2 : Epigenetic Abnormalities of Hematological Malignancies; Basic and Clinical Studies
Chair Dr. Yoshinobu Maeda (Okayama University Hospital)
Dr. Yasushi Miyazaki (Nagasaki University)
Speaker Dr. Hiroyoshi Kunimoto (Yokohama City University Graduate School of Medicine)
Combined TET2/NRAS Mutations Drive Myeloid Leukemia, 5-Aza Resistance and MEK Inhibitor Sensitivity
Dr. Brian Huntly (University of Cambridge, UK)
Epigenetic Dysfunction in AML: H3K27 as a Key Nexus for Transformation
Dr. Shigeru Chiba (University of Tsukuba)
TET2 Dioxygenase Activity in AML Development
Dr. Jaroslaw Maciejewski (Cleveland Clinic, USA)
TBC
17:35-17:45 Break
17:45-18:15 Oral Session : Hematological Malignancies and Their Therapies, Clonal Hematopoiesis
Chair Dr. Atsushi Hirao (Kanazawa University)
Dr. Yoshio Katayama (Kobe University Hospital)
Speaker Dr. Shuhei Asada (The Institute of Medical Science, The University of Tokyo)
A Positive Feedback Loop of Mutant ASXL1 and BAP1 Promotes Myeloid Leukemogenesis
Dr. Norihiro Murakami (Nagoya University Graduate School of Medicine)
Integrated Molecular Profiling of Juvenile Myelomonocytic Leukemia
Dr. Teppei Sakoda (Kyushu University Hospital, Kyushu University Graduate School of Medical Sciences)
Identification of a Novel Wnt Pathway Activation Mechanism Mediated by TIM-3/Gal-9/HCK Axis in Human AML-LSCs
Welcome Reception
Saturday, 28 July, 2018
8:00-8:45 Morning Seminar 1 (Co-Sponsored by Eisai Co., Ltd. )
Chair Dr. Akifumi Takaori-Kondo (Kyoto University)
Speaker Dr. Jonathan D. Licht (University of Florida Health Cancer Centerm, USA)
Epigenetic Regulations in Blood and Other Malignancies -Focus on EZH2-
8:00-8:45 Morning Seminar 2 (Co-Sponsored by SymBio Pharmaceuticals Limited. /Onconova Therapeutics, Inc.)
Chair Dr. Hideki Muramatsu (Nagoya University Graduate School of Medicine)
Speaker Dr. Lewis R Silverman (The Mount Sinai Hospital and School of Medicine, USA)
Rigosertib-Strategies in MDS and Pediatric Rasopathies
8:45-8:50 Break
8:50-10:10 Plenary Session 3 : Clinical Studies and New Epigenetic Therapies for Hematological Malignancies
Chair Dr. Itaru Matsumura (Kindai University)
Dr. Norio Komatsu (Juntendo University)
Speaker Dr. Ravi Majeti (Stanford University, USA)
Epigenetic Dysregulation in Human AML Stem Cells
Dr. Issay Kitabayashi (National Cancer Center Research Institute)
Cancer Stem Cell-Targeted Therapy for Hematological Malignancy Based on Dual Inhibition of EZH1/EZH2
Dr. Jonathan D. Licht (University of Florida Health Cancer Center, USA)
Deregulation and Oncogenic Functions of the NSD2/MMSET Histone Methyl Transferase in Hematological Malignancies
10:10-10:20 Break
10:20-12:00 JSH-ASH Joint Session : Epigenetics of Hematological Malignancies
Chair Dr. Koichi Akashi (Kyushu University)
Dr. Hideaki Nakajima (Yokohama City University Graduate School of Medicine)
Speaker Dr. Omar Abdel-Wahab (Memorial Sloan Kettering Cancer Center, USA)
Coordinated Alterations in RNA Splicing and Epigenetic Regulation Drive Leukemogenesis
Dr. Toshio Kitamura (The Institute of Medical Science, University of Tokyo)
EZH2 Mutations Induce MDS-like Symptoms in Mouse BMT Models via Overexpression of ABC-G2 and Inhibition of Bone Formation
Dr. Seishi Ogawa (Kyoto University)
TBC
Dr. Margaret Goodell (Baylor College of Medicine, USA)
DNA Methyltransferase 3A in Normal and Malignant Hematopoiesis
12:00-12:15 Break
12:15-13:00 Luncheon Seminar 3 (Co-Sponsored by Nippon Shinyaku Co.,Ltd.)
Chair Dr. Hideaki Nakajima (Yokohama City University Graduate School of Medicine)
Speaker Dr. Daniel Starczynowski (Cincinnati Children's Hospital Medical Center : University of Cincinnati, USA)
Novel Therapeutic Targets in Myeloid Malignancies
Luncheon Seminar 4 (Co-Sponsored by Bristol-Myers Squibb K.K.)
Chair Dr. Koichi Akashi (Kyushu University)
Speaker Dr. Brian Huntly (University of Cambridge, UK)
TBC
13:00-13:10 Break
13:10-14:10 Sweets Seminar Special Lecture 1・2 : Epigenetic Aspects of Hematological Malignancies and Their Therapies
Chair Dr. Yuzuru Kanakura (Osaka University Graduate School of Medicine)
Dr. Masahiro Kizaki (Saitama Medical Center, Saitama Medical University)
Speaker Dr. Raphael Itzykson (Hopital Saint-Louis, Assistance Publique Hôpitaux de Paris, Paris Diderot University, France)
Recent Insight on the Clinical Use of Hypomethylating Agents
Dr. Ari Melnick (Weill Cornell Medicine, USA)
Epigenetic Basis of Germinal Center Derived B-cell Lymphomas
14:10-14:15 Closing Remarks
Page Top